MAOB and Parkinson disease: Monoamine oxidase type B (MAOB) inhibitors have elicited neuroprotective effects in preclinical models of PD and longer exposure to these inhibitors have been associated with less clinical decline in PD patients (Hauser et al., 2017) and reduced risk of dyskinesia (Dashtipour et al., 2015).